Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
Authors
Keywords
-
Journal
JOURNAL OF HEADACHE AND PAIN
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-12-31
DOI
10.1186/s10194-021-01368-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
- (2021) J. Talbot et al. JOURNAL OF HEADACHE AND PAIN
- Early outcomes of migraine after erenumab discontinuation: data from a real-life setting
- (2021) Eleonora De Matteis et al. NEUROLOGICAL SCIENCES
- Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study
- (2021) Andreas R Gantenbein et al. CEPHALALGIA
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
- (2021) Egilius L. H. Spierings et al. HEADACHE
- Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study
- (2021) Bianca Raffaelli et al. CEPHALALGIA
- Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults
- (2020) Hans-Christoph Diener et al. CEPHALALGIA
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- Effect of Fremanezumab on Quality of Life and Productivity in Patients With Chronic Migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention
- (2020) J. Schoenen et al. REVUE NEUROLOGIQUE
- Responsiveness and minimal clinically important difference of the EQ-5D-5L in cervical intraepithelial neoplasia: a longitudinal study
- (2020) Xin Hu et al. Health and Quality of Life Outcomes
- Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study
- (2020) Dawn C. Buse et al. JOURNAL OF HEADACHE AND PAIN
- The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
- (2020) Stephen D. Silberstein et al. JOURNAL OF HEADACHE AND PAIN
- Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
- (2020) Janet Ford et al. QUALITY OF LIFE RESEARCH
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
- (2019) Virginia L. Stauffer et al. HEADACHE
- A narrative review on the burden of migraine: when the burden is the impact on people’s life
- (2019) Matilde Leonardi et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in chronic migraine
- (2019) Richard B. Lipton et al. NEUROLOGY
- Population pharmacokinetic modeling and simulation of fremanezumab in healthy subjects and patients with migraine
- (2019) J.B. Fiedler‐Kelly et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
- (2019) William Kielbasa et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Monoclonal antibodies for the prevention of migraine
- (2019) Bianca Raffaelli et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
- (2018) Cristina Tassorelli et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- German Value Set for the EQ-5D-5L
- (2018) Kristina Ludwig et al. PHARMACOECONOMICS
- Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness
- (2018) Amaia Bilbao et al. QUALITY OF LIFE RESEARCH
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab
- (2018) Dawn C Buse et al. CEPHALALGIA
- Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab
- (2018) David W. Ayer et al. HEADACHE
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal Clinically Important Difference in Quality of Life for Patients With Low Back Pain
- (2017) María J. Díaz-Arribas et al. SPINE
- Interictal burden attributable to episodic headache: findings from the Eurolight project
- (2016) Christian Lampl et al. JOURNAL OF HEADACHE AND PAIN
- The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference
- (2016) Claire M Nolan et al. THORAX
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
- (2015) Marcelo E Bigal et al. LANCET NEUROLOGY
- What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients
- (2013) Antonia FH Smelt et al. CEPHALALGIA
- Correlation of Headache Frequency and Psychosocial Impairment in Migraine: A Cross-Sectional Study
- (2013) Ruth Ruscheweyh et al. HEADACHE
- Headache Impact Test-6 (HIT-6) Scores for Migraine Patients: Their Relation to Disability as Measured from a Headache Diary
- (2009) Hae Eun Shin et al. Journal of Clinical Neurology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now